State of the Art Update and Next Questions: Acute Myeloid Leukemia
The past decade has witnessed major advances in our comprehension of the biological heterogeneity of acute myeloid leukemia (AML); however, translating this knowledge into better outcomes for AML patients has lagged. Over the past year, two large, randomized phase III clinical trials with novel therapies produced positive results that are expected to lead to the first new drug approvals in AML in over 40 years.[1, 2] Many other promising drugs are currently under investigation, offering hope that even more novel treatments will be added to the armamentarium in the near future.
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics, and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 (3 days of anthracycline and 7 days of cytarabine) induction and absence of monosomal karyotype to positively predict complete remission whereas positive predictors of overall survival were younger age and the absence of monosomal karyotype.
Outcomes in acute myeloid leukemia (AML) have been correlated with predictive and prognostic factors including age, performance status, comorbidities, cytogenetics and molecular mutations. Retrospective review of 137 adult AML patients identified 3+7 induction and absence of monosomal karyotype to positively predict complete remission while positive predictors of overall survival were younger age and the absence of monosomal karyotype.
Acute myeloid leukemia (AML) is the second most common leukemia among adults. Although the median age at diagnosis is 67 years, with approximately one-third of patients aged 75 years or older, limited treatment options exist for the elderly, who have 5-year survival rates of only 5%. A systematic review was conducted to examine effectiveness and safety outcomes of treatment regimens in elderly ( ≥60 years old) patients with AML.Published literature on the topic was scant, and the review included only 22 articles examining outcomes.
Abstract BACKGROUND: Limited data are available regarding the incidence, survival patterns, and long-term outcomes of natural killer (NK)/T-cell neoplasms in the United States. PATIENTS AND METHODS: We performed a retrospective study of patients with NK/T-cell neoplasms diagnosed from 2001 to 2014 using the Surveillance, Epidemiology, and End Results program database. The Kaplan-Meier method was used to estimate the overall survival difference among the subgroups. Multivariate analyses were used to determine the factors affecting survival. RESULTS: For the 797 patients with NK/T-cell lymphoma, nasal type...
We performed a retrospective population-based study to determine the epidemiology of natural killer (NK)/T-cell neoplasms in the United States. We found that the incidence of NK/T-cell lymphoma doubled during the past decade and is more common in Hispanic population. Unlike NK/T-cell lymphoma, no significant racial disparities were found in NK/T-cell leukemia. The risk of second primary acute myeloid leukemia might be increased for patients with NK/T-cell lymphoma.
This was a retrospective population-based study aimed to determine the epidemiology of NK/T-cell neoplasms in the United States. We noticed that the incidence of NK/T-cell lymphoma doubled over the past decade and is more common in Hispanic population. Unlike NK/T-cell lymphoma, no significant racial disparities exist in NK/T-cell leukemia. There may be an increased risk of second primary acute myeloid leukemia (AML) in patients with NK/T-cell lymphoma.
This report adds to the pool of cases that reveal associations between use of lenalidomide and increased risk of developing secondary primary high-grade astrocytomas in multiple myeloma. PMID: 29616908 [PubMed - in process]
Publication date: Available online 31 March 2018 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Takayoshi Tachibana, Taiki Andou, Masatsugu Tanaka, Satomi Ito, Takuya Miyazaki, Yoshimi Ishii, Eriko Ogusa, Hideyuki Koharazawa, Hiroyuki Takahashi, Kenji Motohashi, Jun Aoki, Yuki Nakajima, Kenji Matsumoto, Maki Hagihara, Chizuko Hashimoto, Jun Taguchi, Katsumichi Fujimaki, Hiroyuki Fujita, Shin Fujisawa, Heiwa Kanamori, Hideaki Nakajima A multicenter retrospective analysis was performed to evaluate the clinical significance of serum ferritin at diagnosis in patients with acute myeloid leukemia. The study cohort inc...
The clinical significance of ferritin at diagnosis in patients with acute myeloid leukemia was examined in a multicenter retrospective study. Elevated ferritin may indicate tumor burden and predict worse event-free survival in the high-risk karyotype group.
We retrospectively evaluated the clinical, cytogenetic, and molecular profiles, and survival outcomes of pediatric acute myeloid leukemias (AMLs) with and without myeloid sarcoma (MS). MS was present in 121 of 570 patients (21.2%). The most frequent site was the orbit. Event-free survival (P = .003) and overall survival (P = .001) were better among AML with MS. The t (8; 21) was significantly associated with MS (odds ratio = 3.92).